A recent FDA-mandated study reveals that over 22% of patients prescribed extended-release painkillers like OxyContin become addicted within a year, significantly surpassing previous claims of less than 1%. This revelation forces the FDA to reconsider regulations and potential label changes for these drugs, which had been widely marketed as safe. The study's troubling findings, which highlight the addictive dangers of long-acting opioids, were delayed for over a decade and are prompting calls for more stringent oversight and ethical considerations due to the harm caused to many patients.
The study even showed that 22.5% of pain patients on extended-release opioids became addicted within a year, significantly more than claims by drugmakers' representatives.
The FDA now faces the question of how to respond to this alarming data, considering changes in opioid regulations and potential label modifications.
Collection
[
|
...
]